data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Prelude Therapeutics

(NASDAQ:PRLD)

Intraday

$3.87

0.02[0.52%]

After-Hours

$4.03

0.1600[4.13%]

Perks Buy Compare Brokers

$3.87

0.02[0.52%]

At close: Apr 23

$4.03

0.1600[4.13%]

After Hours: 7:52AM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Prelude Therapeutics Stock (NASDAQ:PRLD)

Prelude Therapeutics Stock (NASDAQ: PRLD)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, April 10, 2024

Prelude Therapeutics Disclosed Laurent Chardonnet Will No Longer Serve As CFO
Benzinga Newsdesk - Apr 10, 2024, 4:11PM

Wednesday, March 13, 2024

JMP Securities Initiates Coverage On Prelude Therapeutics with Market Outperform Rating, Announces Price Target of $7
Benzinga Newsdesk - Mar 13, 2024, 5:20AM

Tuesday, February 20, 2024

HC Wainwright & Co. Downgrades Prelude Therapeutics to Neutral, Announces $5 Price Target
Benzinga Newsdesk - Feb 20, 2024, 9:03AM

Friday, February 16, 2024

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights - Feb 16, 2024, 12:31PM
Prelude Therapeutics shares are trading higher after the company reported a year-over-year increase in FY23 EPS results.
Benzinga Newsdesk - Feb 16, 2024, 11:12AM

Thursday, February 15, 2024

Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023
Benzinga Newsdesk - Feb 15, 2024, 4:40PM

Tuesday, December 19, 2023

Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
Benzinga Insights - Dec 19, 2023, 12:00PM
Morgan Stanley Downgrades Prelude Therapeutics to Underweight, Lowers Price Target to $4
Benzinga Newsdesk - Dec 19, 2023, 9:33AM

Monday, December 11, 2023

Prelude Therapeutics Entered Into A Securities Purchase Agreement With Institutional Investors, To Which The Company Agreed To Issue And Sell Pre-Funded Warrants To Purchase Up To 7,936,759 Shares Of Voting Common Stock At A Price Of $3.1499 Per Warrant
Benzinga Newsdesk - Dec 11, 2023, 9:24AM

Tuesday, November 07, 2023

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk - Nov 7, 2023, 1:20PM

Wednesday, November 01, 2023

Prelude Therapeutics Q3 EPS $(0.45) Beats $(0.58) Estimate
Benzinga Newsdesk - Nov 1, 2023, 5:50PM
Prelude Therapeutics And AbCellera Enter Partnership To Develop First-In-Class Precision Antibody Drug Conjugates In Oncology
Benzinga Newsdesk - Nov 1, 2023, 5:18PM

Thursday, October 19, 2023

Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday
Lisa Levin - Oct 19, 2023, 8:03AM
The Latest Analyst Ratings for Prelude Therapeutics
Benzinga Insights - Oct 19, 2023, 8:00AM
HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $6
Benzinga Newsdesk - Oct 19, 2023, 7:06AM

Tuesday, October 10, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Oct 10, 2023, 1:09PM

Friday, September 15, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 15, 2023, 11:52AM

Wednesday, August 23, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Aug 23, 2023, 1:16PM

Tuesday, August 22, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Aug 22, 2023, 1:51PM

Thursday, August 17, 2023

HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $17 Price Target
Benzinga Newsdesk - Aug 17, 2023, 6:32AM

Friday, August 04, 2023

Morgan Stanley Reiterates Equal-Weight on Prelude Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk - Aug 4, 2023, 2:46PM
Barclays Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk - Aug 4, 2023, 7:09AM

Thursday, August 03, 2023

Prelude Therapeutics Q2 EPS $(0.54) Beats $(0.63) Estimate; Cash, Cash Equivalents, And Marketable Securities Of $255M Sufficient To Fund Operations Into 2026
Benzinga Newsdesk - Aug 3, 2023, 8:17AM

Wednesday, August 02, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Aug 2, 2023, 1:55PM

Monday, July 31, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Jul 31, 2023, 2:54PM

Friday, July 28, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Jul 28, 2023, 12:36PM

Thursday, July 27, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights - Jul 27, 2023, 12:17PM

Thursday, June 22, 2023

Board Member at Prelude Therapeutics Acquires Company Stock Options Worth 47,000 Shares
Benzinga Insights - Jun 22, 2023, 11:03AM

Thursday, May 25, 2023

5.00M Reasons To Be Bullish On Prelude Therapeutics Stock
Benzinga Insights - May 25, 2023, 11:07AM
Prelude Therapeutics Insider Trades Send a Signal
Benzinga Insights - May 25, 2023, 11:06AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - May 25, 2023, 9:07AM

Thursday, May 18, 2023

Prelude Therapeutics shares are trading lower after the company announced pricing of a public offering.
Benzinga Newsdesk - May 18, 2023, 8:57AM
Prelude Therapeutics Reports Pricing Of Public Offering For Total Gross Proceeds Of $100M
Benzinga Newsdesk - May 18, 2023, 7:06AM

Wednesday, May 17, 2023

Prelude Therapeutics Reports Launch Of Proposed $100M Public Offering Of Shares Of Common Stock
Benzinga Newsdesk - May 17, 2023, 4:11PM

Monday, May 08, 2023

Prelude Therapeutics Q1 EPS $(0.58) Beats $(0.68) Estimate
Happy Mohamed - May 8, 2023, 8:18AM

Friday, March 17, 2023

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $17
Benzinga Newsdesk - Mar 17, 2023, 6:28AM

Wednesday, March 15, 2023

Prelude Therapeutics Q4 EPS $(0.60) Beats $(0.63) Estimate
Happy Mohamed - Mar 15, 2023, 8:45AM
Prelude Therapeutics Announces Clinical Trial Collaboration With BeiGene To Evaluate PRT2527 In Combination With Zanubrutinib In Hematologic Cancers
Bill Haddad - Mar 15, 2023, 8:06AM

Tuesday, January 03, 2023

Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jan 3, 2023, 1:39PM

Wednesday, December 07, 2022

Prelude Therapeutics Shares Resume Trade
Michael Horton - Dec 7, 2022, 4:00PM
Prelude Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down 23.4%
Benzinga Newsdesk - Dec 7, 2022, 3:56PM

Tuesday, November 22, 2022

Carvana, Crocs And Other Big Losers From Monday
Lisa Levin - Nov 22, 2022, 5:21AM

Monday, November 21, 2022

Why This Prelude Therapeutics Analyst Disagrees With 2 Others And Downgraded The Stock
Priya Nigam - Nov 21, 2022, 12:05PM
Expert Ratings for Prelude Therapeutics
Benzinga Insights - Nov 21, 2022, 10:01AM
Analyst Ratings for Prelude Therapeutics
Benzinga Insights - Nov 21, 2022, 9:04AM
B of A Securities Downgrades Prelude Therapeutics to Underperform, Announces $6 Price Target
Benzinga Newsdesk - Nov 21, 2022, 8:28AM

Thursday, November 17, 2022

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $15
Benzinga Newsdesk - Nov 17, 2022, 6:12AM

Tuesday, November 15, 2022

Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $10
Benzinga Newsdesk - Nov 15, 2022, 8:41AM

Monday, November 14, 2022

Prelude Therapeutics Q3 EPS $(0.63) Up From $(0.66) YoY
Benzinga Newsdesk - Nov 14, 2022, 8:16AM

Tuesday, October 18, 2022

Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
Lisa Levin - Oct 18, 2022, 1:31PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved